Acutaas Chemicals Ltd (IN:ACUTAAS)
:ACUTAAS
Want to see IN:ACUTAAS full AI Analyst Report?
ACUTAAS Stock Chart & Stats
₹1747.20
-₹131.70(-5.63%)
At close: 4:00 PM EST
₹1747.20
-₹131.70(-5.63%)
Day’s Range― - ―
52-Week Range₹1,059.05 - ₹3,070.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)14.81K
Market Cap
₹245.78B
Enterprise Value₹244.13B
Total Cash (Recent Filing)₹2.80B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)69.1
Beta1.31
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.09%
Share Statistics
EPS (TTM)27.88
Shares Outstanding81,871,124
10 Day Avg. Volume15,850
30 Day Avg. Volume14,806
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)12.67
Price to Sales (P/S)15.64
P/FCF Ratio-733.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)55.87
Revenue Forecast (FY)₹17.28B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA ~52% revenue acceleration in FY2026 reflects durable demand expansion or successful commercial execution. Sustained high top-line growth supports scale economies, investment in R&D/processing capacity, and provides a multi-quarter runway for margin improvement and market-share gains.
Improved ProfitabilityMaterial margin expansion to ~26.6% net and ~33.2% EBIT in FY2026 suggests improved mix and operating leverage. If structural, these margins enable stronger earnings retention, higher ROE and reinvestment capacity, raising the company’s ability to fund growth and withstand industry cyclicality.
Conservative Balance SheetExtremely low reported leverage provides long-term financial flexibility, lower interest burden and capacity for funded investments or cyclical shocks. A conservative capital structure supports strategic options like capex, M&A or returning capital without straining cash flows.
Bears Say
Negative Free Cash FlowPersistent negative free cash flow, including ~-0.29B in FY2026 despite strong earnings, signals heavy reinvestment or working-capital drain. Over months this can limit self-funding for capex/dividends, force external financing, and magnify risk if operating performance weakens.
Cash-Flow VolatilityVolatile operating cash generation, including a negative OCF year, reduces predictability of internal funding and complicates capital allocation. Such variability increases refinancing and liquidity risk in downturns and makes sustained investment or dividend policies harder to maintain.
Earnings / Margin VolatilityA swing from ~6.0% net margin in FY2024 to much higher in FY2026 indicates earnings sensitivity to mix, input costs or pricing. This lack of consistency raises uncertainty about the durability of recent margin levels and complicates forecasting and long-term return assumptions.
Acutaas Chemicals News
ACUTAAS FAQ
What was Acutaas Chemicals Ltd’s price range in the past 12 months?
Acutaas Chemicals Ltd lowest stock price was ₹1059.05 and its highest was ₹3070.80 in the past 12 months.
What is Acutaas Chemicals Ltd’s market cap?
Acutaas Chemicals Ltd’s market cap is ₹245.78B.
When is Acutaas Chemicals Ltd’s upcoming earnings report date?
Acutaas Chemicals Ltd’s upcoming earnings report date is Aug 06, 2026 which is in 68 days.
How were Acutaas Chemicals Ltd’s earnings last quarter?
Acutaas Chemicals Ltd released its earnings results on Apr 30, 2026. The company reported ₹16.1 earnings per share for the quarter, beating the consensus estimate of ₹13.05 by ₹3.05.
Is Acutaas Chemicals Ltd overvalued?
According to Wall Street analysts Acutaas Chemicals Ltd’s price is currently Overvalued.
Does Acutaas Chemicals Ltd pay dividends?
Acutaas Chemicals Ltd pays a Annually dividend of ₹1.5 which represents an annual dividend yield of 0.09%. See more information on Acutaas Chemicals Ltd dividends here
What is Acutaas Chemicals Ltd’s EPS estimate?
Acutaas Chemicals Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acutaas Chemicals Ltd have?
Acutaas Chemicals Ltd has 81,871,124 shares outstanding.
What happened to Acutaas Chemicals Ltd’s price movement after its last earnings report?
Acutaas Chemicals Ltd reported an EPS of ₹16.1 in its last earnings report, beating expectations of ₹13.05. Following the earnings report the stock price went up 3.841%.
Which hedge fund is a major shareholder of Acutaas Chemicals Ltd?
Currently, no hedge funds are holding shares in IN:ACUTAAS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acutaas Chemicals Ltd
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson's, antidepressant, and anticoagulant applications. It also provides specialty chemicals for use in battery chemicals, personal care, agrochemicals, coatings, electronics, and industrial processes; photoresist chemicals to semiconductor applications; electrolyte additives for lithium battery cells; and parabens, methyl salicylate, and other commodity chemicals for cosmetics, agrochemicals, and fine chemicals. The company was formerly known as Ami Organics Limited and changed its name to Acutaas Chemicals Limited in May 2025. Acutaas Chemicals Limited was founded in 2004 and is based in Surat, India.
Technical Analysis
Alkyl Amines Chemicals Limited
―
Anupam Rasayan India Ltd.
―
Balaji Amines Limited
―
HEG Limited
―
Rallis India Limited
―